207940 - Samsung Biologics Co., Ltd.

207940 Summary

Biopharma

Stock Price & Overview

₩1,447,000 -30,000 (-2.03%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩1,447,000 ≈ US$1,034 · Market cap ₩67.0tn (≈ $47.8bn)

207940 Financial Statements

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	4.56	3.50	2.94	3.00	1.57	1.16	0.70	0.54
Cost of Revenue	2.04	1.79	1.45	1.53	0.84	0.75	0.51	0.39
Gross Profit	2.52	1.71	1.49	1.47	0.73	0.42	0.19	0.15
Selling, General & Administrative	0.45	0.39	0.28	0.48	0.19	0.12	0.10	0.09
Operating Income	2.07	1.32	1.21	0.98	0.54	0.29	0.09	0.06
Finance Income	0.15	0.21	0.17	0.21	0.05	0.03	0.03	0.02
Finance Costs	0.14	0.15	0.15	0.27	0.03	0.04	0.04	0.02
Pretax Income	2.12	1.38	1.23	1.01	0.56	0.27	0.16	0.30
Income Tax Expense	0.50	0.34	0.28	0.21	0.17	0.03	0.05	-0.08
Net Income	1.78	1.08	0.86	0.80	0.39	0.24	0.20	0.22
Total Comprehensive Income	1.78	1.07	0.85	0.81	0.39	0.24	0.20	0.22

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Assets	11.06	17.34	16.05	16.58	7.97	6.42	5.91	5.98
Current Assets	4.41	5.52	5.52	6.46	2.82	1.75	1.36	1.58
Cash & Cash Equivalents	0.15	0.39	0.37	0.89	0.05	0.03	0.13	0.02
Inventories	2.13	2.82	2.64	2.38	1.01	0.65	0.45	0.30
Trade Receivables	0.68	1.17	0.68	0.73	0.37	0.22	0.19	0.12
Non-current Assets	6.65	11.82	10.52	10.12	5.15	4.67	4.56	4.40
Property, Plant & Equipment	6.03	5.37	3.88	3.42	2.21	1.74	1.70	1.72
Intangible Assets	0.06	5.57	5.83	5.96	0.03	0.02	0.02	0.02
Total Liabilities	3.61	6.43	6.22	7.60	2.98	1.83	1.56	1.82
Current Liabilities	2.53	3.85	4.16	4.18	1.11	0.59	0.69	0.71
Non-current Liabilities	1.08	2.58	2.06	3.42	1.87	1.24	0.87	1.11
Total Equity	7.45	10.90	9.83	8.98	4.99	4.60	4.35	4.16
Share Capital	0.12	0.18	0.18	0.18	0.17	0.17	0.17	0.17
Retained Earnings	6.87	5.09	4.00	3.15	2.35	1.95	1.71	1.51

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Cash from Operating Activities	2.25	1.66	1.67	0.95	0.45	0.20	0.01	-0.03
Cash from Investing Activities	-1.86	-1.24	-1.57	-3.11	-0.93	-0.42	0.34	-0.63
Purchase of Property, Plant & Equipment	1.39	1.30	1.00	0.96	0.41	0.14	0.17	0.28
Cash from Financing Activities	-0.62	-0.43	-0.64	3.00	0.50	0.12	-0.24	0.32
Net Change in Cash	-0.24	0.02	-0.52	0.84	0.02	-0.10	0.11	-0.34

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	1.32	1.26	0.31	1.66	1.29	1.30	1.26	1.19	1.16	0.95
Cost of Revenue	0.62	0.58	0.22	0.68	0.57	0.57	0.59	0.64	0.50	0.53
Gross Profit	0.70	0.68	0.09	0.98	0.72	0.73	0.67	0.54	0.66	0.42
Selling, General & Administrative	0.11	0.10	-0.29	0.25	0.24	0.25	0.34	0.21	0.22	0.20
Operating Income	0.59	0.58	0.38	0.73	0.48	0.49	0.33	0.34	0.43	0.22
Finance Income	0.03	0.08	-0.02	0.04	0.07	0.07	0.17	0.02	0.11	0.08
Finance Costs	0.02	0.02	-0.07	0.00	0.14	0.07	0.05	0.07	0.08	0.06
Pretax Income	0.58	0.64	0.44	0.77	0.41	0.50	0.37	0.29	0.46	0.24
Income Tax Expense	0.15	0.17	0.10	0.19	0.08	0.12	0.05	0.03	0.15	0.06
Net Income	0.43	0.47	0.51	0.57	0.32	0.38	0.32	0.26	0.32	0.18
Total Comprehensive Income	0.44	0.47	0.50	0.58	0.32	0.38	0.31	0.26	0.32	0.18

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	12.65	11.99	11.06	18.34	17.77	17.44	17.34	16.03	16.34	16.52
Current Assets	5.33	4.66	4.41	6.36	5.71	5.26	5.52	4.81	5.43	5.60
Cash & Cash Equivalents	0.29	0.52	0.15	0.92	0.71	0.75	0.39	0.54	0.97	1.06
Inventories	2.34	2.29	2.13	3.12	3.08	2.87	2.82	2.69	2.76	2.66
Trade Receivables	0.62	0.57	0.68	1.07	0.82	0.90	1.17	0.98	0.93	0.69
Non-current Assets	7.32	7.33	6.65	11.98	12.06	12.17	11.82	11.22	10.91	10.92
Property, Plant & Equipment	6.47	6.46	6.03	6.17	5.76	5.80	5.37	4.68	4.36	4.33
Intangible Assets	0.08	0.08	0.06	5.39	5.45	5.51	5.57	5.68	5.74	5.79
Total Liabilities	4.29	4.07	3.61	6.16	6.17	6.16	6.43	5.43	6.01	6.51
Current Liabilities	2.97	2.74	2.53	3.77	3.64	3.62	3.85	3.56	4.03	4.65
Non-current Liabilities	1.32	1.33	1.08	2.39	2.53	2.54	2.58	1.87	1.98	1.87
Total Equity	8.36	7.92	7.45	12.18	11.60	11.28	10.90	10.59	10.33	10.01
Share Capital	0.12	0.12	0.12	0.18	0.18	0.18	0.18	0.18	0.18	0.18
Retained Earnings	7.77	7.34	6.87	6.36	5.79	5.46	5.09	4.77	4.50	4.18

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	0.62	0.77	0.42	0.62	0.52	0.68	0.39	0.74	0.24	0.29
Cash from Investing Activities	-0.91	-0.40	-0.86	-0.21	-0.54	-0.25	-1.07	-0.44	-0.32	0.58
Purchase of Property, Plant & Equipment	0.09	0.09	0.54	0.09	0.13	0.62	0.57	0.55	0.10	0.08
Cash from Financing Activities	0.04	-0.00	-0.35	-0.20	-0.00	-0.07	0.51	-0.71	-0.03	-0.20
Net Change in Cash	-0.23	0.37	-0.77	0.21	-0.04	0.36	-0.15	-0.43	-0.09	0.69

Consolidated (CFS), from DART. 8 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

207940 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	4,557.0	+30.3%	+14.9%	+31.4%	—
Operating income	2,069.2	+56.6%	+28.1%	+47.9%	—
Net income	1,784.4	+64.7%	+30.8%	+49.2%	—
EPS	₩38,546	+64.7%	+30.8%	+49.2%	—
Operating cash flow	2,247.8	+35.5%	+33.1%	+61.9%	—
Shareholders' equity	7,451.1	-31.7%	-6.0%	+10.1%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

207940 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	55.2%	48.9%	50.7%	48.9%	46.3%	35.7%
Operating margin	45.4%	37.8%	41.0%	32.8%	34.3%	25.1%
Net margin	39.2%	31.0%	29.2%	26.6%	25.1%	20.7%
Return on equity	19.4%	10.4%	9.1%	11.4%	8.2%	5.4%
Return on assets	12.6%	6.5%	5.3%	6.5%	5.5%	3.9%
Operating cash flow / revenue	49.3%	47.4%	56.7%	31.8%	29.0%	17.4%
Capex / revenue	30.5%	37.3%	33.9%	31.9%	25.9%	12.0%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 207940

Symbol	Last Price
068270Celltrion, Inc.	₩188,100 +0.5%
196170Alteogen Inc.	₩288,500 +1.9%
326030SK biopharmaceuticals Co., Ltd.	₩86,600 +0.2%
128940Hanmi Pharm. Co., Ltd.	₩473,500 +2.8%
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.